Does use of a school-wide integrated pest management (IPM) program or high-efficiency particulate air (HEPA) filter purifiers in the classrooms reduce asthma symptoms in students with active asthma?
This factorial randomized clinical trial included 236 students (attending 41 elementary schools with 209 classrooms) randomized to an IPM program at the school level, use of HEPA filter purifiers at the classroom level, or both. Use of the school-wide IPM program resulted in a mean of 1.5 symptom-days with asthma during a 2-week period vs 1.9 symptom-days for no IPM; use of HEPA filter purifiers resulted in a mean of 1.6 symptom-days with asthma vs 1.8 symptom-days for sham HEPA filter purifiers; neither comparison was statistically significant.
Among children with active asthma, use of a school-wide IPM program or HEPA filter purifiers in the classrooms did not significantly reduce symptom-days with asthma.
School and classroom allergens and particles are associated with asthma morbidity, but the benefit of environmental remediation is not known.
To determine whether use of a school-wide integrated pest management (IPM) program or high-efficiency particulate air (HEPA) filter purifiers in the classrooms improve asthma symptoms in students with active asthma.
Design, Setting, and Participants
Factorial randomized clinical trial of a school-wide IPM program and HEPA filter purifiers in the classrooms was conducted from 2015 to 2020 (School Inner-City Asthma Intervention Study). There were 236 students with active asthma attending 41 participating urban elementary schools located in the Northeastern US who were randomized to IPM by school and HEPA filter purifiers by classroom. The date of final follow-up was June 20, 2020.
The school-wide IPM program consisted of application of rodenticide, sealing entry points, trap placement, targeted cleaning, and brief educational handouts for school staff. Infestation was assessed every 3 months, with additional treatments as needed. Control schools received no IPM, cleaning, or education. Classroom portable HEPA filter purifiers were deployed and the filters were changed every 3 months. Control classrooms received sham HEPA filters that looked and sounded like active HEPA filter purifiers. Randomization was done independently (split-plot design), with matching by the number of enrolled students to ensure a nearly exact 1:1 student ratio for each intervention with 118 students randomized to each group. Participants, investigators, and those assessing outcomes were blinded to the interventions.
Main Outcomes and Measures
The primary outcome was the number of symptom-days with asthma during a 2-week period. Symptom-days were assessed every 2 months during the 10 months after randomization.
Among the 236 students who were randomized (mean age, 8.1 [SD, 2.0] years; 113 [48%] female), all completed the trial. At baseline, the 2-week mean was 2.2 (SD, 3.9) symptom-days with asthma and 98% of the classrooms had detectable levels of mouse allergen. The results were pooled because there was no statistically significant difference between the 2 interventions (P = .18 for interaction). During a 2-week period, the mean was 1.5 symptom-days with asthma after use of the school-wide IPM program vs 1.9 symptom-days after no IPM across the school year (incidence rate ratio, 0.71 [95% CI, 0.38-1.33]), which was not statistically significantly different. During a 2-week period, the mean was 1.6 symptom-days with asthma after use of HEPA filter purifiers in the classrooms vs 1.8 symptom-days after use of sham HEPA filter purifiers across the school year (incidence rate ratio, 1.47 [95% CI, 0.79-2.75]), which was not statistically significantly different. There were no intervention-related adverse events.
Conclusions and Relevance
Among children with active asthma, use of a school-wide IPM program or classroom HEPA filter purifiers did not significantly reduce symptom-days with asthma. However, interpretation of the study findings may need to consider allergen levels, particle exposures, and asthma symptoms at baseline.
ClinicalTrials.gov Identifier: NCT02291302
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Wanda Phipatanakul, MD, MS, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115 (firstname.lastname@example.org).
Accepted for Publication: June 27, 2021.
Author Contributions: Drs Phipatanakul and Coull had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Phipatanakul, Koutrakis, Coull, Petty, Sheehan, Samnaliev, Baxi, Hauptman, Adamkiewicz, Baccarelli, Gold.
Acquisition, analysis, or interpretation of data: Phipatanakul, Coull, Petty, Gaffin, Sheehan, Lai, Bartnikas, Kang, Wolfson, Samnaliev, Cunningham, Baxi, Permaul, Hauptman, Trivedi, Louisias, Liang, Thorne, Metwali, Israel, Baccarelli, Gold.
Drafting of the manuscript: Phipatanakul, Coull, Petty, Sheehan, Bartnikas, Kang, Baxi, Metwali.
Critical revision of the manuscript for important intellectual content: Phipatanakul, Koutrakis, Coull, Petty, Gaffin, Sheehan, Lai, Bartnikas, Wolfson, Samnaliev, Cunningham, Baxi, Permaul, Hauptman, Trivedi, Louisias, Liang, Thorne, Adamkiewicz, Israel, Baccarelli, Gold.
Statistical analysis: Phipatanakul, Coull, Petty, Sheehan, Lai, Hauptman, Liang, Israel.
Obtained funding: Phipatanakul, Liang, Gold.
Administrative, technical, or material support: Phipatanakul, Kang, Cunningham, Baxi, Permaul, Trivedi, Louisias, Thorne, Metwali.
Supervision: Phipatanakul, Koutrakis, Coull, Gaffin, Wolfson, Cunningham, Baxi, Louisias, Adamkiewicz.
Conflict of Interest Disclosures: Dr Phipatanakul reported receiving nonfinancial support from Coway Co Ltd (provided HEPA filter intervention), ALK-Abelló (provided skin testing reagents), and Monaghen (provided aerochambers); receiving grants from Thermo Fisher and the National Institutes of Health; receiving consulting fees from Genentech/Novartis, Regeneron/Sanofi, and GlaxoSmithKline; receiving funding, clinical trial support, and medications from Genentech/Novartis, Regeneron/Sanofi, and GlaxoSmithKline; and receiving clinical trial medication support from Bohringer Ingelheim, AstraZeneca, Merck, and CSL Behring. Dr Coull reported receiving grants from Apple Inc. Dr Sheehan reported receiving consulting fees from GlaxoSmithKline for serving on an advisory board. Dr Louisias reported receiving grants from the Brigham and Women’s Hospital Nesson Fellowship. Dr Israel reported receiving personal fees from the National Asthma Education and Prevention Program for serving on the coordinating committee, which advises on the asthma guidelines for the US. No other disclosures were reported.
Funding/Support: Coway Co Ltd provided the HEPA filter purifiers. Other in-kind materials were provided by ALK-Abelló, Lincoln Diagnostics, and Thermo Fisher Scientific. This study was supported by grants 5K12HS022986-03, 8UL1TR000170, P30ES031663, P30ES000002, K23ES023700, K23AI104780, K23AI106945, K23AI123517, K23AI143962, K24AI106822, K23HL150341, L30HL143781, P30ES005605, and U01AI110397 from the National Institutes of Health. Additional support was provided by grants DW-75-95877701, NU61TS000296, RD-834798, and RD-835872 from the US Environmental Protection Agency. This work also was supported by the Harvard Catalyst/Harvard Clinical and Translational Science Center and Harvard University and its affiliated academic health care centers.
Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The members of the School Inner-City Asthma Intervention study team appear in Supplement 3.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the Harvard Catalyst/Harvard Clinical and Translational Science Center, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health. In addition, the US Environmental Protection Agency does not endorse the purchase of any commercial products or services mentioned in the publication.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We thank the pest management teams from Buono Pest Control Co Inc and the pest management consultants, Rivard’s Resources, who received compensation for their services. We also thank the participating schools, the students, and their families for the support they provided for the study. This study was additionally monitored by independent monitors at Pharmaceutical Product Development LLC.
You currently have no searches saved.
You currently have no courses saved.